4 Animals AlsterScience GmbH develops innovative therapies for animals. Through targeted use of natural immunomodulators immune function is significantly improved and in sick and old animals optimally restored.
AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biological drugs in indications with unmet medical needs.
Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.
AudioCure Pharma specializes in the preclinical and clinical development of small molecules for the treatment of audiological and neurodegenerative diseases like sudden hearing loss, tinnitus, Parkinson’s and Alzheimer’s disease. In a first step the company focuses on sudden hearing loss.
Our compounds AC102 and AC002 have shown excellent efficacy in different animal models for the above-mentioned indications. Consequently, AudioCure is on its way to perform formal preclinical tests and to move AC102 into first-in-man testing.
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.
Exit since June 2012.
GeneQuine Biotherapeutics is a biotech company focused on the development of gene therapy-based drugs for treatment of musculoskeletal disorders. In the lead program GeneQuine develops drug candidates with potentially disease-modifying activity for treatment of osteoarthritis.
In 2017, one of GeneQuine's lead candidates was acquired by the US pharma company Flexion Therapeutics Inc.
Immunic AG is a start-up biotech company founded in April 2016 and focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and RORyt (IMU-366 program) relevant to diseases such as Crohn’s disease and psoriasis. The final aim is to develop these drug candidates to clinical proof of concept. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors.
Immunservice GmbH develops biomimetic immune hormones, in particular interleukin-2, for safer, more effective and potentially curative therapies, especially in cancer.
MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.
OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I).
Development of novel therapeutic approaches addressing infectious and autoimmune diseases as well as cancers via immune cell-specific targeting.
Thermosome develops novel drugs for locally-advanced solid tumors by using nanocarriers for heat-induced local drug delivery and thereby reaches up to 15 fold higher local drug concentrations.
Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.